Short Description:
CAS number： 93106-60-6
Molecular formula：C19H22FN3O3
molecular weight：359.39
Chemical structure：
| Basic Information | |
| Product name | Enrofloxacin Base |
| Grade | pharmaceutical grade |
| Appearance | Yellow or lighy orange-yellow, crystalline powfer |
| Assay | 99% |
| Shelf life | 3 Years |
| Packing | 25kg/carton |
| Condition | stored in a cool and dry place |
Product Description
This product is oral, intramuscular and subcutaneous injection, and is easily absorbed, widely distributed in vivo, in addition to the central nervous system, the concentration of the drug in other organizations, almost all are higher than the blood concentration.Enrofloxacin can be used as veterinary medicines. It has a long half-time in animals and good dispersion degree, which belongs to the broad spectrum of antibacterial agent.
Enrofloxacin is a broad spectrum bactericidal drugs, have special effects on mycoplasma. White on escherichia coli, klebsiella bacillus coli, pseudomonas aeruginosa, salmonella, deformation, haemophilus, kill, pasteurella, streptococcus hemolytic pap coli, s. aureus bacteria, such as have antiseptic effect.
Function
Dogs and Cats
The product is indicated in the treatment of bacterial infections of the alimentary, respiratory and urogenital tracts, skin, secondary wound infections and otitis externa where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.
Cattle
Diseases of the respiratory and alimentary tract of bacterial or mycoplasmal origin (e.g. pasteurellosis, mycoplasmosis, coli-bacillosis, coli-septicaemia and salmonellosis) and secondary bacterial infections subsequent to viral conditions (e.g. viral pneumonia) where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.
Pigs
Diseases of the respiratory and alimentary tract of bacterial or mycoplasmal origin (e.g. pasteurellosis, actinobacillosis, mycoplasmosis, coli-bacillosis, coli-septicaemia and salmonellosis) and mulifactorial diseases such as atrophic rhinitis and enzootic pneumonia, where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.
